Based on the Soligenix Inc stock forecast from 0 analysts, the average analyst target price for Soligenix Inc is not available over the next 12 months. Soligenix Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Soligenix Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Soligenix Inc’s stock price was USD 1.95. Soligenix Inc’s stock price has changed by -11.76% over the past week, -17.58% over the past month and -73.68% over the last year.
No recent analyst target price found for Soligenix Inc
No recent average analyst rating found for Soligenix Inc
Company Overview Soligenix Inc
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. Read Less
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeu...Read More
Frequently Asked Questions About Soligenix Inc (SNGX) Stock
Stock Target Advisor's fundamental analysis for Soligenix Inc's stock is Bearish.
Unfortunately we do not have enough data on SNGX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on SNGX's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on SNGX's stock to indicate if its overvalued.
The last closing price of SNGX's stock was USD 1.95.
The most recent market capitalization for SNGX is USD 5.77M.
Unfortunately we do not have enough analyst data on SNGX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Soligenix Inc's stock.
As per our most recent records Soligenix Inc has 13 Employees.
Soligenix Inc's registered address is 29 Emmons Drive, Princeton, NJ, United States, 08540.
You can get more information about it from Soligenix Inc's website at https://www.soligenix.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Soligenix Inc (SNGX) Stock
Stock Target Advisor's fundamental analysis for Soligenix Inc's stock is Bearish.
Unfortunately we do not have enough data on SNGX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on SNGX's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on SNGX's stock to indicate if its overvalued.
The last closing price of SNGX's stock was USD 1.95.
The most recent market capitalization for SNGX is USD 5.77M.
Unfortunately we do not have enough analyst data on SNGX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Soligenix Inc's stock.
As per our most recent records Soligenix Inc has 13 Employees.
Soligenix Inc's registered address is 29 Emmons Drive, Princeton, NJ, United States, 08540.
You can get more information about it from Soligenix Inc's website at https://www.soligenix.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SNGX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
